Oct. 18, 2024 – The trial, led by Imperial College London, will focus on whether psilocybin – the active compound in magic mushrooms – combined with psychological support, can help to prevent relapse in people who have been addicted to opioids such as heroin. Combining Imperial’s expertise in psychedelics and opioid addiction, the work will be led by Dr David Erritzoe from the Centre for Psychedelic Research.
The trial will recruit those who have recently undergone detoxification from street opioids such as heroin, or opioid replacements like methadone or buprenorphine. Participants will visit Imperial’s NIHR Clinical Research Facility, which is based at Hammersmith Hospital campus and hosted by Imperial College Healthcare NHS Trust, to receive psilocybin therapy.
EMR MATTERS – October 2024 - The challenge is that many in the behavioral health…
TOO LITTLE, TOO LATE? – Dec. 19, 2024 - Assembly Bill 56 (AB 56) proposes…
AND STOPPED DIGGING – Dec. 4, 2024 - In a new interview with The Times,…
NOT JUST IN PENCILS – Dec. 8, 2024 - Americans born before 1966 experienced “significantly…
AS SUCCESSFUL AS EVER – Dec. 3, 2024 - Family Affair actor Johnny Whitaker looked…
ALANON Plus – Dec. 7, 2024 - A high percentage of treatment failures occur due…